This article is more than 5 years old. Information may no longer be current.

Acucela enrolls patients in trial for oral AMD agent

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

Acucela Inc. announced that it has completed enrollment in its ongoing phase 2b/3 clinical trial investigating the oral agent, emixustat, in subjects with geographic atrophy.

The Safety and Efficacy Assessment Treatment Trials of Emixustat HCl (SEATTLE) study is a multicenter, randomized, double-masked, dose-ranging trial initiated in early 2013, the company reported in a press release.

Emixustat is being studied in 508 patients with geographic atrophy associated with dry age-related macular degeneration to determine if the agent slows the rate of progression of geographic atrophy lesions, the company reported.

“Completing enrollment in this trial ahead of schedule represents a tremendous achievement for the program,” Ryo Kubota, MD, PhD, Acucela chairman, president and CEO, stated in the release.